Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response

Cancer Biotherapy & Radiopharmaceuticals
Ruby Meredith

Abstract

Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in a progressive series of clinical trials after basic science, human cell culture and animal model studies. Toxicities during these trials are graded using common scoring systems that are in widespread use such as the Common Toxicity Criteria from the National Cancer Institute. Information on normal tissue toxicity from radionuclides is more limited than that from external beam radiation and is more variable. Variability is likely due to many biologic factors as well as less precise dose quantitation than those used in external beam radiation practice. As expected based on known radiobiologic effects, tolerance to radionuclide therapy appears to exceed that from high dose rate external beam radiation in most organs. Although the correlation between reported dose estimates and toxicity has progressively and substantially improved over the past two decades, further progress is needed to establish optimal toxicity predictive relationships. Continued refinement of dosimetry techniques and standardization is expected to increase the accuracy and comparability of radiation dose reports between institutions as well as improve dose/respons...Continue Reading

References

Jul 1, 1976·Medical Physics·S R ThomasJ G Kereiakes
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·J R WilliamsL E Dillehay
Feb 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S J KnoxB W Wessels
Jun 11, 1992·Gynecologic Oncology·W J SpanosS Pursell
Sep 1, 1991·The British Journal of Radiology·A H LaingM A Zivanovic
Nov 1, 1991·International Journal of Radiation Oncology, Biology, Physics·E J Hall, D J Brenner
Feb 1, 1991·International Journal of Radiation Oncology, Biology, Physics·M J EvansJ P Harrell
Apr 1, 1991·International Journal of Radiation Oncology, Biology, Physics·J Y WongX W Yan
Jan 1, 1990·European Journal of Nuclear Medicine·R B RichardsonL S Lashford
Mar 1, 1990·International Journal of Radiation Oncology, Biology, Physics·B N GrayL Matz
Dec 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E OrderK Finney
Feb 1, 1989·International Journal of Radiation Oncology, Biology, Physics·J S StewartH E Lambert
Dec 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A EpenetosG B Sivolapenko
Oct 21, 1993·The New England Journal of Medicine·O W PressB Porter
Jul 1, 1994·Medical Physics·J F EaryI Bernstein
Oct 20, 1993·International Journal of Radiation Oncology, Biology, Physics·R M MacklisJ L Humm
Aug 1, 1993·British Journal of Cancer·V HirdA A Epenetos
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F CellaJ Brannon
Mar 1, 1993·Medical Physics·V K LangmuirJ Y Wong
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S KaminskiR L Wahl
Dec 1, 1996·International Journal of Radiation Oncology, Biology, Physics·S E OrderP E Wallner
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·S J DeNardoG L DeNardo
Mar 23, 2000·Seminars in Radiation Oncology·S J Knox, R F Meredith
Mar 23, 2000·Seminars in Radiation Oncology·I R McDougall
Mar 23, 2000·Seminars in Radiation Oncology·A J McEwan
Mar 23, 2000·Seminars in Radiation Oncology·A D Murtha
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·H B BreitzP L Weiden
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·M N SalehD J Buchsbaum
Jan 5, 2002·Current Pharmaceutical Biotechnology·R F Meredith, S J Knox
Mar 28, 2002·Cancer Biotherapy & Radiopharmaceuticals·Hazel Breitz

❮ Previous
Next ❯

Citations

Aug 22, 2009·Cancer Biotherapy & Radiopharmaceuticals·Yuni K DewarajaAnca M Avram
Jun 9, 2005·Nuclear Medicine Communications·Hubert M ThierensKlaus Bacher
Jun 9, 2005·Nuclear Medicine Communications·Klaus Bacher, Hubert M Thierens
Jul 30, 2008·Seminars in Nuclear Medicine·Ruby MeredithSusan Knox
Mar 15, 2016·Nuclear Medicine Communications·Madhav P YadavChandrasekhar Bal
Jun 23, 2006·Physics in Medicine and Biology·Michael Stabin
May 27, 2004·Radiation Research·Bieke LambertAndreas Otte
Nov 22, 2020·Scientific Reports·Yaser H GholamiZdenka Kuncic
Jul 5, 2006·Molecular Cancer Therapeutics·Gregory Z FerlJoseph J DiStefano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Radiation Oncology, Biology, Physics
Rachel K BodeyGlenn D Flux
Cancer Biotherapy & Radiopharmaceuticals
H B Breitz
Cancer Biotherapy & Radiopharmaceuticals
Gerald L DeNardoSally J DeNardo
© 2022 Meta ULC. All rights reserved